Tempus AI (TEM) Projected to Announce Earnings on Monday

Tempus AI (NASDAQ:TEM) is anticipated to announce its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.0808) per share and revenue of $409.39 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:45 AM ET.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.22) EPS. On average, analysts expect Tempus AI to post ($1.43) EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Tempus AI Stock Performance

Shares of TEM opened at $67.61 on Monday. The firm has a 50-day moving average price of $69.24 and a 200 day moving average price of $57.26. The firm has a market capitalization of $12.20 billion, a PE ratio of -46.95 and a beta of 3.54. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI has a 52-week low of $40.77 and a 52-week high of $93.38.

Insider Activity at Tempus AI

In related news, EVP Andrew Polovin sold 2,951 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $221,325.00. Following the completion of the transaction, the executive vice president owned 135,189 shares in the company, valued at $10,139,175. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the transaction, the chief executive officer owned 15,874 shares of the company’s stock, valued at $1,111,180. This trade represents a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,280,965 shares of company stock valued at $80,397,564 over the last ninety days. Company insiders own 24.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. UBS Group assumed coverage on shares of Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price target on the stock. Roth Capital started coverage on shares of Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Rothschild & Co Redburn assumed coverage on shares of Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective on the stock. Finally, Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Eleven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $72.37.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
• Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
• Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
• Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.